Some micro-evidence on the "Porter Hypothesis" from Austrian VOC emission standards

In the context of the discussion on the 'Porter Hypothesis', a sizeable amount of research has been devoted to empirical tests of the impact of environmental regulation on both competitiveness and innovation. The standard practice is to regress some measure of regulatory stringency on some measure of competitiveness and innovation across several industries and/or countries. However, possibly due to measurement problems, the results of these studies tend to be inconclusive and if any effects are found, these are usually rather small. Addressing the measurement problem, this paper uses highly disaggregated foreign trade data and data from a full survey of the Austrian paint, coatings, printing inks and adhesive industry to examine the impact of Austrian VOC emission standards on Austrian manufacturers of the regulated products. These standards are particularly interesting in that they are the most restrictive of their kind in the world and therefore an excellent case to study some of the issues raised by the 'Porter Hypothesis'. Based on various measures of RCA, I find no impact (i.e. neither negative nor positive) on competitiveness, which is also supported by the industry's own evaluation in the survey. I do find, however, that the regulations restricted imports. An important corollary of this finding is that the industry's current attempt to have the more restrictive Austrian regulation relaxed to the more lenient provisions of the European VOC directive may be counterproductive, since contrary to popular belief this may increase import competition rather than facilitate exports. Second, I consider various indicators of innovation based on evidence from the survey. I find that the regulation induced sizeable changes of firms' product range which vary by technological sub-segment. These changes are also reflected in a more dynamic technological environment. R&D spending to develop compliant products is found to be very unevenly distributed. While some firms spent virtually nothing, other firms devoted almost their complete R&D budget to compliance innovations. This result is mainly a function of technology and to a lesser extent of organisational factors. Moreover, there is evidence that the introduction of compliant products displaced or postponed existing R&D projects, again with substantial variations by technology. Finally, the survey produces evidence that compliance efforts yielded new ideas and allowed some firms to acquire new competencies and technologies, which they would not have acquired in the absence of the regulation. However, the latter finding is most probably due to technologically backward (small) firms catching up. To summarise, the survey evidence reveals considerable heterogeneity in how firms were affected and responded to the regulation. Partly, this is an expected result of a uniform command-and-control regulation, partly it indicates a differential ability of firms to adapt to an external shock. Although based on a very small sample, the paper points to interesting lines of enquiry that should be explored in future research.

Does technology affect network structure? - A quantitative analysis of collaborative research projects in two specific EU programmes

The promotion of collaborative R&D through Framework Programmes is a top priority of European RTD policy. However, despite the considerable sums involved, surprisingly little is known about the structure of the resulting research networks. Arguing that the underlying technological regime critically affects the structure of collaborative R&D, this article examines the structure and topology of collaborative research networks in the telecommunications and the agro-industrial industry in two specific programmes of the 4th EU Framework Programme. We find systematic differences which we attribute to differences in the underlying knowledge base, the research trajectories pursued in EU-funded R&D and the organisation of knowledge production in the two industries. As expected on the basis of prior research, we show that collaborative research projects involve a larger number of partners and require greater funding in the telecommunications industry, and that actors from science are positioned more prominently in the agro-industrial collaborative R&D network. Contrary to expectations, we find fewer and less intense interactions between science and industry in the agro-industrial industry. We provide a tentative explanation for this result and discuss policy implications.framework programmes, research collaborations, technological regime, sectoral innovation system, social network analysis, science-industry interactions

R&D collaboration networks in the European FrameworkProgrammes: Data processing, network construction and selected results

We describe the construction of a large and novel data set on R&D collaboration networks in the first five EU Framework Programmes (FPs), examine key features and provide economic interpretations for our findings. The data set is based on publicly available raw data that pre-sents numerous challenges. We critically examine the different problems and detail how we have dealt with them. We describe how we construct networks from the processed data. The resulting networks display properties typical for large complex networks, including scale-free degree distributions and the small-world property. The former indicates the presence of net-work hubs, which we identify. Theoretical work shows the latter to be beneficial for knowl-edge creation and diffusion. Structural features are remarkably similar across FPs, indicating similar network formation mechanisms despite changes in governance rules. Several findings point towards the existence of a stable core of interlinked actors since the early FPs with inte-gration increasing over time. This core consists mainly of universities and research organisa-tions. The paper concludes with an agenda for future research.R&D collaboration, EU Framework Programmes, complex networks, small world effect, knowledge creation, knowledge diffusion, European Research Area

The Determinants of Pharmaceutical R&D Expenditures: Evidence from Japan

During the past 20 years, the world pharmaceutical industry has experienced a dramatic increase in R&D intensity. We apply and extend a model developed by Grabowski and Vernon (2000) with a pooled data sample of the 15 publicly listed Japanese drug firms for the period 1987 to 1998. As in the reference paper, we find expected returns to be an important determinant of R&D spending in the Japanese drug industry, albeit considerably smaller than in the U.S., which is particularly obvious in the case of returns from newly introduced drugs. However, our results are sensitive to econometric model specification, in particular to controlling for serial correlation and to a dynamic specification of the baseline model. Likewise, estimates on financial constraints are sensitive to model specification, indicating that Japanese drug firms face small or no financial constraints. Our results are consistent with the general literature on R&D investment behaviour, yet raise some methodological questions with regard to the original study.R&D, investment, panel data estimation, pharmaceuticals, Japan

The Changing Nature of Pharmaceutical R&D - Opportunities for Asia?

During the 1990''s, the pharmaceutical R&D process has witnessed tremendous technological changes. The emergence of new tools like ''combinatorial chemistry'', ''high throughput screening'' and the in-creasing use of computer-aided in silico experiments has led to significant improvements of research efficiency. This paper discusses the economic impact of this trend. It is argued that the resulting radical improvements in R&D productivity have lowered the minimum efficient scale in pharmeceutical research. As a consequence, the main bottleneck in pharmaceutical research has shifted from the mechanical act of synthesising and screening a sufficient number of active compounds to scientific excellence. Empirical finding indicate that the latter can more easily be achieved in smaller, highly focused firms. Accordingly, the most efficient way to currently conduct pharmaceutical R&D may be a new ''division of labour'' in research between small, highly specialised firms conducting research and large firms focusing on the development, testing, and marketing or new drugs. This reopens a ''window of opportunity'' for Asian pharmaceutical firms who had lost out in the previous race to ever increasing size.economics of technology ;

The structure of R&D collaboration networks in the European Framework Programmes

Using a large and novel data source, we study the structure of R&D collaboration net-works in the first five EU Framework Programmes (FPs). The networks display proper-ties typical for complex networks, including scale-free degree distributions and the small-world property. Structural features are common across FPs, indicating similar network formation mechanisms despite changes in governance rules. Several findings point towards the existence of a stable core of interlinked actors since the early FPs with integration increasing over time. This core consists mainly of universities and research organisations. We observe assortative mixing by degree of projects, but not by degree of organisations. Unexpectedly, we find only weak association between central projects and project size, suggesting that different types of projects attract different groups of actors. In particular, large projects appear to have included few of the pivotal actors in the networks studied. Central projects only partially mirror funding priorities, indicating field-specific differences in network structures. The paper concludes with an agenda for future research.R&D collaboration, EU Framework Programmes, Complex Networks, Small World Effect, Centrality Measures, European Research Area

Distinct spatial characteristics of industrial and public research collaborations: Evidence from the 5th EU Framework Programme

This study compares the spatial characteristics of industrial R&D networks to those of public research R&D networks (i.e. universities and research organisations). The objective is to measure the impact of geographical separation effects on the constitution of cross-region R&D collaborations for both types of collaboration. We use data on joint research projects funded by the 5th European Framework Programme (FP) to proxy cross-region collaborative activities. The study area is composed of 255 NUTS-2 regions that cover the EU-25 member states (excluding Malta and Cyprus) as well as Norway and Switzerland. We adopt spatial interaction models to analyse how the variation of cross-region industry and public research networks is affected by geography. The results of the spatial analysis provide evidence that geographical factors significantly affect patterns of industrial R&D collaboration, while in the public research sector effects of geography are much smaller. However, the results show that technological distance is the most important factor for both industry and public research cooperative activities.Comment: 28 page

The Determinants of Pharmaceutical R&D Expenditures: Evidence from Japan

During the past 20 years, the world pharmaceutical industry has experienced a dramatic increase in R&D intensity. We apply and extend a model developed by Grabowski and Vernon (2000, Journal of Evolutionary Economics, 10, 201–215) with a pooled data sample of the 15 publicly listed Japanese drug firms for the period 1987–1998. As in the original study, we find expected returns to be an important determinant of R&D spending in the Japanese drug industry, albeit considerably smaller than in the U.S., which is particularly obvious in the case of returns from newly introduced drugs. However, our results are sensitive to econometric model specification, in particular to controlling for serial correlation and to a dynamic specification of the baseline model. Likewise, estimates on financial constraints are sensitive to model specification, indicating that Japanese drug firms face small or no financial constraints. Our results are consistent with the general literature on R&D investment behaviour, yet raise some methodological questions with regard to the original study. Copyright Springer 2006investment, Japan, panel data estimation, pharmaceuticals, R&D, L65, O31, O33,